书目详情:
Front MatterPart I. Background and IntroductionChapter 1. Restenosis following percutaneous coronary interventionsChapter 2. Histopathology of restenosisChapter 3. Cellular mechanisms of restenosisChapter 4. Molecular basis of restenosis and potential therapeutic targetsChapter 5. Principles of continuum pharmacokinetics in stent-based drug elutionChapter 6. Importance of the toxic/therapeutic windowChapter 7. Drug delivery coatingsChapter 8. The importance of the drug platformPart II. Drug–Stent ProgramsChapter 9. Rapamycin structure and mechanism of actionChapter 10. Sirolimus-coated stentChapter 11. Nonrandomized registries for de novo lesions (FIM) and in-stentrestenosisChapter 12. The RAVEL trialChapter 13. The SIRIUS, E-SIRIUS and C-SIRIUS trialsChapter 14. Sirolimus-eluting coronary stent in high-risk patients with complexl esionsChapter 15. Local vascular delivery of paclitaxelChapter 16. Preclinical experience with the paclitaxel-eluting stentChapter 17. The Quanam drug-eluting stent and the SCORE trialChapter 18. Initial experiences with paclitaxel-eluting stents for treatment of de novo as well as in-stent restenotic lesionsChapter 19. The Boston Scientific Taxus trialsChapter 20. Local delivery of paclitaxel as a stent coatingChapter 21. Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT)Chapter 22. PATENCY Pilot studyChapter 23. Paclitaxel-eluting stents—the ELUTES trialChapter 24. Vascular Endothelial Growth Factor (VEGF)-eluting stentsChapter 25. The Millennium Matrix™ Coronary StentChapter 26. The Conor drug delivery stentChapter 27. Actinomycin-eluting stent for coronary revascularizationChapter 28. Guidant deliver II studyChapter 29. Guidant deliver clinical trialChapter 30. BatimastatChapter 31. The prevention and treatment of in-stent restenosis—the current challenge for coronary interventionChapter 32. DexamethasoneChapter 33. 17_-estradiol-eluting stents—a potential therapy in the prevention of restenosisChapter 34. An advanced antisense (AVI-4126) for local and stent-based delivery for prevention of restenosis after PCI (current status and future developments)Chapter 35. The Endeavor Drug-Eluting Stent programChapter 36. Terumo statin releasing stent (preclinical results)Chapter 37. Duraflex™ Drug-Eluting Coronary Stent SystemChapter 38. Genous™ Bio-engineered R stent™Chapter 39. Everolimus-eluting stentsChapter 40. Contemporary state of drug-eluting stentsChapter. Index
评论:

